MyFinsight
Home
Blog
About
Cash and cash
equivalents
$3,431K
(-59.34%↓ Y/Y)
Prepaid expenses and
other current assets
$562K
(-69.17%↓ Y/Y)
Total current assets
$3,993K
(-61.09%↓ Y/Y)
Operating lease
right-of-use asset
$931K
(-20.50%↓ Y/Y)
Other assets
$863K
(2875.86%↑ Y/Y)
Property and equipment,
net
$123K
(-38.50%↓ Y/Y)
Total assets
$5,910K
(-49.32%↓ Y/Y)
Accumulated deficit
-$483,767K
(-12.73%↓ Y/Y)
Total liabilities and
stockholders' deficit
$5,910K
(-49.32%↓ Y/Y)
Total stockholders'
deficit
-$15,361K
(3.10%↑ Y/Y)
Additional paid-in capital
$468,396K
(13.34%↑ Y/Y)
Class a common stock,
0.0001 par value...
$10K
(11.11%↑ Y/Y)
Total liabilities
$21,271K
(-22.69%↓ Y/Y)
Warrant liabilities
$11,367K
(435.67%↑ Y/Y)
Total current
liabilities
$7,342K
(-19.57%↓ Y/Y)
Convertible notes at fair
value, including...
$1,755K
(-88.43%↓ Y/Y)
Operating lease liability
$757K
(-25.78%↓ Y/Y)
Contingent consideration
liability
$27K
(-60.87%↓ Y/Y)
Other liabilities
$23K
Accounts payable
$2,697K
(-30.97%↓ Y/Y)
Accrued compensation
$1,897K
(247.44%↑ Y/Y)
Other accrued
expenses
$1,815K
(-39.52%↓ Y/Y)
Accrued clinical trials
expenses
$933K
(-44.30%↓ Y/Y)
Back
Back
Balance Sheet
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)
source: myfinsight.com